XClose

UCL-TB

Home
Menu

Dr Patrick Phillips

Senior Statistician, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Pop Health Sciences

Dr Patrick Phillips is senior statistician and programme leader track at the UK Medical Research Council Clinical Trials Unit (MRC CTU) at UCL. He has worked on late-phase clinical trials in tuberculosis and Alzheimer’s disease for more than a decade, most recently as trial statistician in the REMoxTB and RIFAQUIN phase III TB trials published in 2014. He is part of the European/African PanACEA consortium evaluating novel regimens for the treatment of TB, designing the PanACEA MAMS-TB phase II trial with an adaptive design with results to be published in 2015. He is trial statistician for the STREAM trial evaluating novel MDR-TB regimens, is trial statistician and PI for the MRC/DFID/Wellcome grant for the TRUNCATE trial collaborating with the National University of Singapore, and is in collaboration with individuals from the CDC TB Trials Consortium and Boston University on other clinical trials to improve the treatment of TB. His PhD from the London School of Hygiene and Tropical Medicine focused on the evaluation of prognostic and surrogate markers for TB treatment trials. Ongoing methodological areas of interest include the evaluation and use of surrogate endpoints, the conduct and analysis of non-inferiority trials and trial design with a focus on adaptive designs.

Dr Patrick Phillips

Dr Patrick Phillips

Address

Aviation House
125 Kingsway
London
WC2B 6NH

Appointments

  • Principal Research Associate
    MRC Clinical Trials Unit at UCL
    Inst of Clinical Trials &Methodology

Joined UCL

2005-10-10

Dr Patrick Phillips is senior statistician and programme leader track at the MRC Clinical Trials Unit at UCL. He has worked on late-phase clinical trials in tuberculosis for more than a decade, most recently as trial statistician in the EDCTP-funded REMoxTB and RIFAQUIN phase III TB trials published in 2014. He is part of the EDCTP-funded European/African PanACEA consortium evaluating novel regimens for the treatment of TB, designing the PanACEA MAMS-TB phase II trial with an adaptive design published in 2016. He is lead statistician for the STREAM trial evaluating novel shorter MDR-TB regimens, and for the TRUNCATE-TB trial evaluating 2-3 month regimens for drug-sensitive TB in East Asia. Ongoing methodological areas of interest include the evaluation and use of surrogate endpoints, the conduct and analysis of non-inferiority trials and trial design with a focus on adaptive designs.